Toxicity | Percentage of patients | |||||||||
Gem+E (n=132)* | Cap+E (n=124)* | |||||||||
Grade | Grade | |||||||||
1 | 2 | 3 | 4 | All | 1 | 2 | 3 | 4 | All | |
Leucocytopenia | 23 | 29 | 7 | 1 | 60 | 7 | 3 | 0 | 0 | 10 |
Thrombocytopenia | 20 | 14 | 8 | 3 | 45 | 3 | 1 | 2 | 0 | 6 |
Anaemia | 21 | 35 | 11 | 2 | 69 | 21 | 15 | 5 | 0 | 41 |
Infection | 9 | 22 | 14 | 4 | 49 | 6 | 12 | 12 | 1 | 31 |
Diarrhoea | 23 | 23 | 6 | 1 | 53 | 29 | 20 | 9 | 3 | 61 |
Nausea | 30 | 30 | 8 | 0 | 68 | 24 | 26 | 5 | 0 | 55 |
Vomiting | 21 | 18 | 4 | 1 | 44 | 13 | 17 | 3 | 1 | 34 |
Stomatitis | 9 | 8 | 2 | 0 | 19 | 22 | 9 | 3 | 0 | 34 |
Skin rash | 25 | 32 | 9 | 1 | 67 | 31 | 23 | 6 | 1 | 61 |
Hand–foot syndrome | 8 | 2 | 0 | 0 | 10 | 19 | 13 | 6 | 0 | 38 |
Pneumonitis | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
Cap, capecitabine; E, erlotinib; Gem, gemcitabine.
↵* Safety population (n=256).